Lab Corp. (NYSE: LH) reported Q4 EPS of $2.86, $0.06 better than the analyst estimate of $2.80. Revenue for the quarter came in at $3 billion versus the consensus estimate of $2.93 billion.

GUIDANCE:

Lab Corp. sees FY2020 EPS of $11.75-$12.15, versus the consensus of $11.98.

• Revenue growth of 4.0% to 6.0% over 2019 revenue of $11.55 billion, which includes the negative impact from the disposition of business of approximately 0.2% as well as the benefit from foreign currency translation of 0.4%.
• Revenue growth in LabCorp Diagnostics of 0.5% to 2.5% over 2019 revenue of $7.00 billion, which includes the negative impact from PAMA of approximately 1.3% as well as the benefit from one additional revenue day of 0.4% and foreign currency translation of 0.1%.
• Revenue growth in Covance Drug Development of 7.0% to 9.5% over 2019 revenue of $4.58 billion, which includes the negative impact from the disposition of business of approximately 0.5% as well as the benefit from foreign currency translation of 0.7%.
• Adjusted EPS of $11.75 to $12.15, an increase of 3.8% to 7.3% over 2019 adjusted EPS of $11.32.
• Free cash flow (operating cash flow less capital expenditures) of $950 million to $1.05 billion, compared to $1.04 billion in 2019.

For earnings history and earnings-related data on Lab Corp. (LH) click here.